An Open-Label, Multicentre, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumours or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma
This is a multicentre, open-label, Phase 1/2 study that is being conducted in two parts. The
Phase 1 part (closed to accrual as of January 25, 2016) is comprised of dose escalation and
expansion parts to establish the MTD and/or the recommended Phase 2 dose (RP2D) when
tazemetostat is given BID (twice daily) orally on a continuous basis. Additionally, in
separate cohorts in Phase 1, the effect of food on the bioavailability of tazemetostat as
well as the drug-drug interaction (DDI) potential of tazemetostat are being evaluated. The
Phase 2 part was initiated once the MTD and /or RP2D was established. Phase 2 enrolls
subjects with DLBCL (Cohorts 1-3 and 6) and FL (Cohorts 4 and 5) for the determination of
efficacy and safety of tazemetostat monotherapy (Cohorts 1-5) and of tazemetostat in
combination with prednisolone (Cohort 6) with placement determined by centrally confirmed
histology, cell of origin (COO), and EZH2 mutation status.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society